Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor

Sponsor
Aalborg University (Other)
Overall Status
Completed
CT.gov ID
NCT04554888
Collaborator
(none)
20
1
2
4
5

Study Details

Study Description

Brief Summary

In this experiment the investigators would like to assess if papain induces an itch sensation comparable to the itch sensation induced by cowhage and to confirm that the mechanism of action of papain follows the non-histaminergic pathway.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor
Actual Study Start Date :
Mar 1, 2022
Actual Primary Completion Date :
May 31, 2022
Actual Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Doxepin Application

During the session each forearm of the subject will be divided into four squared areas (2.5x2.5 cm), see Figure 4. Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours 48. At the end of the pre-treatment period, the patches will be removed and the skin will be cleaned with alcohol.

Drug: Doxepin Topical
Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours

Experimental: Itch Induction

After Doxepin removal, Then tests with papain, cowhage, histamine or vehicle will be conducted. Each substance will be randomly applied in two areas, one pretreated with doxepin and one with no pre-treatment.

Drug: Papain
Papain will be applied by 1 SPT prick thought the skin

Drug: Histamine
Histamine will be applied by 1 SPT prick thought the skin

Other: Cowhage
Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.

Outcome Measures

Primary Outcome Measures

  1. Superficial blood perfusion [15 minutes]

    Superficial blood perfusion is measured by a Speckle contrast imager (FLPI, Moor Instruments, England).

  2. Measuring itch intensity by computerized Visual Analog Scale Scoring [15 minutes]

    The subjects will rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable" and similarly for sensations of stinging/pricking and burning, both of which are frequently associated with the sensation of itch.

  3. Measuring pain intensity by computerized Visual Analog Scale Scoring [15 minutes]

    The subjects will rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable".

  4. Measuring Alloknesis [15 minutes]

    Alloknesis is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 milliNewton of force). This stimulator is applied 0.5 cm outside the area of itch provocation.

Secondary Outcome Measures

  1. Measurement of Cold Detection Thresholds (CDT) [15 minutes]

    The tests for thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature decreases 1°C per second from a starting temperature of 32°C until the subject perceives a temperature change (cold sensation) and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 0°C will be used.

  2. Measurement of Cold PainThresholds (CPT) [15 minutes]

    The tests for thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature decreases 1°C per second from a starting temperature of 32°C until the subject perceives a temperature change (cold sensation) and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 0°C will be used.

  3. Measurement of Heat Pain Thresholds (HPT) [15 minutes]

    The tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature raises 1°C per second from a starting temperature of 32°C until the subject detects a painful sensation and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 52°C will be used.

  4. Measurement of Warm Detection Thresholds (WDT) [15 minutes]

    The tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature raises 1°C per second from a starting temperature of 32°C until the subject detects a painful sensation and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 52°C will be used.

  5. Measurement of Pain to Supra-threshold Heat Stimuli [15 minutes]

    The tests will be conducted by using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. The subjects will have to rate the pain to two suprathreshold heat pain stimuli (starting and ending at 32°C with an increase and decrease of 5°C and 3 s plateau at 50°C).

  6. Measurement of Mechanical Pain Thresholds (MPT) [15 minutes]

    This test is conducted using a pin-prick set (Aalborg University, Aalborg). This test is conducted using a pin-prick set (Aalborg University, Aalborg).easurement of Mechanical Pain Thresholds (MPT)

  7. Measurement of Mechanical Pain Sensitivity (MPS) [15 minutes]

    This test is conducted using a pin-prick set (Aalborg University, Aalborg).

  8. Touch Pleasantness (TP) [15 minutes]

    Pleasant touch sensation measured using astandardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy men and women

  • 18-60 years

  • Speak and understand English

Exclusion Criteria:
  • Pregnancy or lactation

  • Drug addiction defined as any use of cannabis, opioids or other addictive drugs

  • Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.).

  • Lack of ability to cooperate

  • Current use of medications that may affect the trial such as antihistamines, antipsychotics and pain killers, as well as systemic or topical steroids.

  • Skin diseases

  • Moles, scars or tattoos in the area to be treated or tested.

  • Hypersensitivity to papaya and mango fruit, cashew nuts, rubber latex

  • Consumption of alcohol or painkillers 24 hours before the study days and between these

  • Acute or chronic pain

  • Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aalborg University Aalborg Nordjylland Denmark 9000

Sponsors and Collaborators

  • Aalborg University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Silvia Lo Vecchio, PhD, Assistant Professor, Aalborg University
ClinicalTrials.gov Identifier:
NCT04554888
Other Study ID Numbers:
  • N-20200005 2nd project
First Posted:
Sep 18, 2020
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022